Bone density & osteoporosis
Peptides acting on bone metabolism — such as PTH analogues driving anabolism or calcitonin inhibiting resorption. Several are approved drugs; use is strictly physician-directed.
Peptides on this topic
3 peptides researched for this topicAbaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein (PTHrP 1-34). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis in postmenopausal women at high fracture risk. Like the related teriparatide, studies describe it as stimulating new bone formation, but it exhibits a distinct receptor-binding profile.
- Human RCTReduction in the incidence of new vertebral fractures in postmenopausal women with osteoporosis compared with placebo.
Salmon calcitonin is a synthetically produced 32-amino-acid peptide hormone that corresponds to the body's own calcitonin but exhibits higher biological potency than the human hormone. In the scientific literature it is studied in the context of inhibiting osteoclast-mediated bone resorption and lowering elevated calcium levels. It was historically broadly approved for the treatment of postmenopausal osteoporosis; following European safety reviews, however, its use was restricted.
- Human trialReduction of bone-turnover markers and clinical efficacy in Paget's disease of bone, including lowering of elevated alkaline phosphatase levels.
Teriparatide is the recombinant N-terminal fragment 1-34 of human parathyroid hormone (PTH). It is regulatory-approved and studied in the scientific literature as a bone-anabolic agent for the treatment of osteoporosis. Unlike antiresorptive agents, studies attribute to it an effect that stimulates new bone formation.
- Human RCTReduction in the incidence of new vertebral fractures in postmenopausal women with osteoporosis compared with placebo.